Equities

Charlie Hospital Semarang Tbk PT

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RSCH:JKT

Charlie Hospital Semarang Tbk PT

Actions
Health CareHealth Care Providers
  • Price (IDR)400.00
  • Today's Change4.00 / 1.01%
  • Shares traded5.83m
  • 1 Year change+66.67%
  • Beta--
Data delayed at least 10 minutes, as of Feb 18 2026 09:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PT Charlie Hospital Semarang Tbk is an Indonesia-based company. The Company is engaged in the activities of private hospitals. The Company operates in the field of health and hospitals segment. Its Medical Services include 24-hour emergency room, central surgical installation, Specialist Polyclinic services, Central Surgical Installation, ICU (intensive care unit), HCU (high care unit), Perina, Laboratory, Radiology, Pharmacy, and other supporting facilities. Its Specialist Polyclinic services include surgical polyclinic, dental polyclinic, ophthalmology polyclinic, poly obgyn (womb), SARAF polyclinic, internal medicine polyclinic, ENT polyclinic, paediatric polyclinic, skin & venereal polyclinic, mental health polyclinic, and medical rehabilitation polyclinic.

  • Revenue in IDR (TTM)58.84bn
  • Net income in IDR-18.17bn
  • Incorporated--
  • Employees212.00
  • Location
    Charlie Hospital Semarang Tbk PTJl. Raya Ngabean Kav 1AKel., Ngabean, Kec. Boja Kab. KendalKENDAL 51381IndonesiaIDN
  • Phone+62 2 486005000
  • Websitehttps://charliehospital.co.id/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Royal Prima Tbk PT332.14bn-7.20bn268.08bn752.00--0.27964.770.8071-2.12-2.1297.88282.570.313.524.11441,673,300.00-0.67442.21-0.74522.3927.4330.67-2.186.751.01--0.00--12.8211.43-570.23--29.76--
Diagnos Laboratorium Utama PT Tbk-100.00bn-100.00bn380.00bn111.00--1.96----------154.79----------10.96--12.06--47.10--11.833.27--0.3089--11.9326.01105.47-39.5773.94--
Kedoya Adyaraya Tbk PT448.65bn33.83bn911.08bn751.0026.931.1014.052.0336.3936.39482.59887.930.460621.048.00631,899,500.003.473.463.843.9231.9837.177.537.690.9147--0.0248--18.129.1557.5811.8419.28--
Charlie Hospital Semarang Tbk PT58.84bn-18.17bn1.05tn212.00--7.955,937.6817.84-6.86-6.8622.2049.830.24938.999.79274,933,100.00-7.71---7.98--18.35---30.91--7.97-1.490.5139--15.04---215.93------
Bundamedik Tbk PT1.55tn12.40bn1.63tn1.58k131.860.951312.201.051.441.44180.47199.720.419119.9910.15998,473,500.000.50564.750.74786.7745.1046.961.218.231.892.170.3804--4.4710.0160.08-9.7026.63--
Murni Sadar Tbk PT1.26tn51.08bn2.20tn4.02k43.131.4710.501.7424.6924.69610.48724.900.505924.916.41400,251,900.001.902.572.463.1829.6230.143.764.290.42171.950.3269--15.8219.20140.37--10.90--
Prodia Widyahusada Tbk PT2.23tn190.37bn2.24tn2.95k11.470.92035.151.00208.30208.302,436.942,596.960.839226.0513.19754,324,800.007.1514.087.6815.4758.1859.718.5216.036.15--0.009359.931.345.243.975.1422.179.05
Data as of Feb 18 2026. Currency figures normalised to Charlie Hospital Semarang Tbk PT's reporting currency: Indonesian Rupiah IDR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.